TaiMed CEO Dr. Jimmy Chang to give an exclusive Company Presentation, and Dr. Jing-Yi Huang to present precision immune therapies research adapting antibody-drug conjugate technology for CD4-targeted approaches to HIV reservoir elimination.

TaiMed Biologics Inc. (4147.TWO), a globally-oriented biologics company in HIV and CD4-targeted biologics, today announced that it will showcase its pioneering drug development platform at the upcoming 2026 BIO Asia-Taiwan conference, taking place July 15-19 in Taipei, Taiwan. The company will feature two major sessions highlighting its scientific breakthroughs and pipeline strategy

Dr. Jimmy Chang, CEO of TaiMed Biologics, will give the company presentation to expand on TaiMed's mission to address unmet medical needs globally. Dr. Chang will demonstrate TaiMed's existing commercial portfolio and established manufacturing capability, cementing the company's role as a driving force in global biotechnology innovation, alongside Dr. Jing-Yi Huang, Senior Director of Research & Development of TaiMed Biologics, will deliver a featured presentation titled "A TMB-365-Based CD4-Targeted ADC Platform for HIV Functional Cure and Precision Immune Therapies." 

• Dr. Jing-Yi Huang presentation is scheduled for Thursday, July 16, 2026, from 11:00 AM to 11:15 AM as part of "Special Forum-1: Next Generation ADCs.” The session will take place in Room 403 at the Taipei Nangang Exhibition Center, Hall 1 (TaiNEX1).

• CEO, Dr. Jmmy Chang presentation is scheduled for Thursday, July 16, 2026, from 01:30 PM to 13:45 PM, "TaiMed Biologics Company Presentation”. The session will take place in Booth 913 at the Taipei Nangang Exhibition Center, Hall 1 (TaiNEX1).

While Antibody-Drug Conjugates (ADCs) have revolutionized the oncology sector over the last decade, TaiMed Biologics is exploring the application of ADC technology beyond oncology, including CD4-targeted approaches for infectious disease. The presentation will introduce a novel therapeutic concept leveraging TMB-365—TaiMed's proprietary, second-generation monoclonal antibody directed against the CD4 receptor—engineered into a targeted ADC platform. This innovative approach aims to target and selectively eliminate reservoirs of HIV-infected cells, providing a potential pathway toward a functional cure and driving the future of precision immune therapies.

"Adapting the structural specificity of our TMB-365 platform into an advanced CD4-targeted ADC represents a paradigm shift in TaiMed’s approach to HIV management, moving from lifelong viral suppression toward a functional cure,” said Dr. Jimmy Chang, CEO of TaiMed Biologics. "By combining precision targeting with potent therapeutic payloads designed to address persistent viral reservoirs, TaiMed is pursuing durable, treatment-free remission for people living with HIV. We’re eager to share our latest preclinical insights and R&D strategies with the global scientific community at BIO Asia-Taiwan 2026."

The BIO Asia-Taiwan 2026 conference brings together biotechnology leaders, researchers, and policymakers from across the globe to discuss breakthrough achievements and promote international collaborations. TaiMed's inclusion in the Next Generation ADC forum highlights the expanding clinical versatility of conjugate platforms and reinforces the company's position at the cutting edge of global biotechnology innovation.